ÂÜÀòÂÒÂ×

Daniel Gladwell is currently working as the Chief Scientific Officer and Chief of HTA Strategy at Lumanity since March 2022. Previously, Daniel held various positions at BresMed from July 2011 to March 2022, including Chief Strategy Officer and Head of Corporate Strategy. Prior to that, Daniel worked as a Health Economist at Takeda Pharmaceuticals Europe Ltd from July 2009 to June 2011. Daniel holds a PhD in Health Economics from The University of Sheffield, an MSc in Health Economics from the University of York, and a BA in Economics and Politics from the University of York.